EA201992688A1 - Средства, пути применения и способы лечения - Google Patents
Средства, пути применения и способы леченияInfo
- Publication number
- EA201992688A1 EA201992688A1 EA201992688A EA201992688A EA201992688A1 EA 201992688 A1 EA201992688 A1 EA 201992688A1 EA 201992688 A EA201992688 A EA 201992688A EA 201992688 A EA201992688 A EA 201992688A EA 201992688 A1 EA201992688 A1 EA 201992688A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- ways
- methods
- application
- antibodies
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 102100037632 Progranulin Human genes 0.000 abstract 1
- 102000019204 Progranulins Human genes 0.000 abstract 1
- 108010012809 Progranulins Proteins 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700419 | 2017-07-20 | ||
| PCT/EP2018/069460 WO2019016247A2 (en) | 2017-07-20 | 2018-07-18 | AGENTS, USES AND METHODS OF TREATMENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992688A1 true EA201992688A1 (ru) | 2020-05-20 |
Family
ID=63113476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992688A EA201992688A1 (ru) | 2017-07-20 | 2018-07-18 | Средства, пути применения и способы лечения |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10894833B2 (enExample) |
| EP (1) | EP3655438A2 (enExample) |
| JP (2) | JP7563975B2 (enExample) |
| KR (1) | KR102800556B1 (enExample) |
| CN (3) | CN110945029B (enExample) |
| AR (1) | AR112563A1 (enExample) |
| AU (1) | AU2018303175B2 (enExample) |
| BR (1) | BR112019005428A2 (enExample) |
| CA (1) | CA3069391A1 (enExample) |
| CL (1) | CL2020000070A1 (enExample) |
| CO (1) | CO2019014090A2 (enExample) |
| CR (1) | CR20200027A (enExample) |
| DO (1) | DOP2020000006A (enExample) |
| EA (1) | EA201992688A1 (enExample) |
| EC (1) | ECSP20002935A (enExample) |
| IL (1) | IL271728B2 (enExample) |
| JO (1) | JOP20200007A1 (enExample) |
| MA (1) | MA49633A (enExample) |
| NI (1) | NI202000005A (enExample) |
| PE (1) | PE20210467A1 (enExample) |
| PH (1) | PH12019502869A1 (enExample) |
| RU (1) | RU2019140933A (enExample) |
| SG (1) | SG11201912228WA (enExample) |
| TW (1) | TW201908342A (enExample) |
| WO (1) | WO2019016247A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6999421B2 (ja) | 2015-04-07 | 2022-02-04 | アレクトル エルエルシー | 抗ソルチリン抗体及びその使用方法 |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| EP3917564A4 (en) * | 2019-02-01 | 2022-12-21 | NovaRock Biotherapeutics, Ltd. | ANTI-CLAUDINE 18 ANTIBODIES AND THEIR METHODS OF USE |
| CA3140023A1 (en) * | 2019-06-11 | 2020-12-17 | Alector Llc | Anti-sortilin antibodies for use in therapy |
| CN116249717A (zh) * | 2020-06-24 | 2023-06-09 | 普罗塞纳生物科学有限公司 | 识别分拣蛋白的抗体 |
| CA3252861A1 (en) | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce the degradation of extracellular targets in lysosomes |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE69032742T2 (de) | 1989-08-09 | 1999-06-17 | Rhomed, Inc., Albuquerque, N.Mex. | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| ATE384744T1 (de) | 1999-07-29 | 2008-02-15 | Medarex Inc | Menschliche antikörper gegen her2/neu |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| JP2005538706A (ja) | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| EP1891966B1 (en) | 2002-12-20 | 2012-02-15 | H. Lundbeck A/S | Modulation of activity of neurotrophins; screening method |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
| DK3225251T3 (da) | 2006-12-21 | 2020-03-16 | H Lundbeck As | Modulering af pro-neurotrofinaktivitet |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| CN102006882B (zh) * | 2008-01-16 | 2017-06-06 | 神经动力公司 | 利用颗粒体蛋白前体(pgrn)治疗神经变性疾病 |
| US8377701B2 (en) | 2008-04-27 | 2013-02-19 | H. Lundbeck A/S | Specific ligands to sortilin |
| JP2011524741A (ja) * | 2008-05-27 | 2011-09-08 | 協和発酵キリン株式会社 | インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法 |
| US20120039865A1 (en) | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| EP2379593A2 (en) | 2008-12-19 | 2011-10-26 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| WO2014071131A1 (en) | 2012-11-02 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
| WO2015143300A1 (en) * | 2014-03-21 | 2015-09-24 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
| KR20230109785A (ko) * | 2014-03-27 | 2023-07-20 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
| JP6999421B2 (ja) | 2015-04-07 | 2022-02-04 | アレクトル エルエルシー | 抗ソルチリン抗体及びその使用方法 |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| AU2018247916B2 (en) * | 2017-04-05 | 2025-04-24 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
| PE20210186A1 (es) * | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| CN113151432A (zh) * | 2020-04-14 | 2021-07-23 | 郁金泰 | 神经退行性疾病检测和治疗的新靶标 |
-
2018
- 2018-07-17 US US16/037,790 patent/US10894833B2/en active Active
- 2018-07-18 RU RU2019140933A patent/RU2019140933A/ru unknown
- 2018-07-18 EP EP18750343.8A patent/EP3655438A2/en active Pending
- 2018-07-18 BR BR112019005428A patent/BR112019005428A2/pt not_active IP Right Cessation
- 2018-07-18 WO PCT/EP2018/069460 patent/WO2019016247A2/en not_active Ceased
- 2018-07-18 PE PE2020000100A patent/PE20210467A1/es unknown
- 2018-07-18 CN CN201880047918.8A patent/CN110945029B/zh active Active
- 2018-07-18 JP JP2020502415A patent/JP7563975B2/ja active Active
- 2018-07-18 MA MA049633A patent/MA49633A/fr unknown
- 2018-07-18 JO JOP/2020/0007A patent/JOP20200007A1/ar unknown
- 2018-07-18 CA CA3069391A patent/CA3069391A1/en active Pending
- 2018-07-18 CR CR20200027A patent/CR20200027A/es unknown
- 2018-07-18 SG SG11201912228WA patent/SG11201912228WA/en unknown
- 2018-07-18 KR KR1020207001250A patent/KR102800556B1/ko active Active
- 2018-07-18 AU AU2018303175A patent/AU2018303175B2/en active Active
- 2018-07-18 CN CN202411383796.3A patent/CN119161481A/zh active Pending
- 2018-07-18 EA EA201992688A patent/EA201992688A1/ru unknown
- 2018-07-18 CN CN202411383695.6A patent/CN119161480A/zh active Pending
- 2018-07-18 IL IL271728A patent/IL271728B2/en unknown
- 2018-07-19 TW TW107124976A patent/TW201908342A/zh unknown
- 2018-07-20 AR ARP180102043 patent/AR112563A1/es not_active Application Discontinuation
-
2019
- 2019-12-13 CO CONC2019/0014090A patent/CO2019014090A2/es unknown
- 2019-12-18 PH PH12019502869A patent/PH12019502869A1/en unknown
-
2020
- 2020-01-09 CL CL2020000070A patent/CL2020000070A1/es unknown
- 2020-01-09 DO DO2020000006A patent/DOP2020000006A/es unknown
- 2020-01-16 EC ECSENADI20202935A patent/ECSP20002935A/es unknown
- 2020-01-17 NI NI202000005A patent/NI202000005A/es unknown
- 2020-12-11 US US17/118,934 patent/US20210292414A1/en active Pending
-
2024
- 2024-05-28 JP JP2024085982A patent/JP2024119866A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992688A1 (ru) | Средства, пути применения и способы лечения | |
| PH12018500062A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| TN2018000419A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof. | |
| EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
| EA201791590A1 (ru) | Антитела к tau и их применение | |
| MY201701A (en) | Optimized antibody compositions for treatment of ocular disorders | |
| JOP20190247A1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| PH12018500100A1 (en) | Antibodies that bind to sortilin and inhibit the binding of progranulin | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| WO2018071504A3 (en) | Methods of treating diseases with il-23a antibody | |
| MX393805B (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
| MY206530A (en) | Methods for treating neurodegenerative disorders | |
| GEP20247700B (en) | Antibody variants | |
| MA42270B1 (fr) | Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38 |